|
|
Overview
Highlights
News
Chart
Contacts
|
|
|
|
|
|
|
|
|
| | "Intellectual property includes
over 150 issued U.S. patents and 185 pending U.S. patent applications.
The combined global company has over 1,500 employees worldwide."
|
| |
|
| |
|
|
|
| Approximate
Financial Snapshot as of 10/10/07 |
|
| Shares
Outstanding |
85.01M |
| 52
Wk Hi/Lo |
9.81/
5.28
|
| Market
Cap |
$567M |
| Recent
Price |
$6.67 |
|
|
|
|
|
|
10/10/07
Angiotech
Pharmaceuticals (ANPI)

Website:
www.angiotech.com
Redefining
Success
Overview
Angiotech Pharmaceuticals (ANPI)
operates as a specialty pharmaceutical and medical device company. It
discovers, develops, and markets technologies and medical products for local
diseases and complications associated with medical device implants, surgical
interventions, and acute injury.
ANPI offers various technologies that improve
the performance of medical devices and the outcomes of surgical procedures.
These technologies include various drug, drug delivery, and surface
modification materials and other medical biomaterials designed to be applied
across a range of medical devices and technologies, surgical procedures, and
medical disciplines.
Angiotech also manufactures and markets
single use, specialty medical devices, with products focused primarily on
general surgery; oncology and tumor biopsy; interventional radiology and
vascular surgery; ophthalmology; and aesthetic surgery.
Its product candidates that are undergoing
human clinical trials include TAXUS Liberte paclitaxel-eluting coronary
stent system, which is related to the use of paclitaxel to prevent
restenosis and other local inflammatory diseases; ZILVER PTX paclitaxel-eluting
peripheral vascular stent that is designed for placement in diseased
arteries in the limbs to restore blood flow; Vascular Wrap, a paclitaxel-eluting
mesh surgical implant designed to treat complications associated with
vascular graft implants in patients undergoing hemodialysis or have
peripheral artery disease; and Anti-Infective Catheter related to central
venous catheters.
Angiotech has license agreements with Boston
Scientific Corporation, Cook Group Incorporated, and a distribution and
license agreement with Orthovita Inc. The Company also has a
manufacturing and supply agreement with Baxter Healthcare Corporation; a
collaboration agreement with Genzyme Corporation and CombinatoRx Inc, and a
strategic
alliance agreement with Athersys Inc.
Intellectual property includes
over 150 issued U.S. patents and 185 pending U.S. patent applications.
The combined global company has over 1,500 employees worldwide.
This is an abbreviated profile
and we encourage readers interested in learning more about Angiotech
Pharmaceuticals to visit
the company website at www.angiotech.com.
ANPI
Investor Highlights
- Announced that it intends
to file Premarket Notification 510(k) documents with the U.S. Food and
Drug Administration (FDA) for its innovative, anti-infective
5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC).
- Announced that it has received FDA and CE
Mark approval to begin marketing additional diameters of its Quill
Self-Retaining System Polydioxanone product line in the U.S. and Europe.
- Announced that it reached a favorable
agreement with Johnson & Johnson's subsidiary, Conor Medsystems to
settle all outstanding patent litigation with respect to Conor's CoStar
paclitaxel stent.
- Announced that the U.S. Food and Drug
Administration (FDA) has given clearance to begin marketing the Hemo-Stream
chronic dialysis catheter.
- Total revenue for the 2nd quarter as
adjusted for non-recurring items, was $75.3 million. Total revenue under
generally accepted accounting principles ("GAAP") was $72.4
million.
Recent
News and Press Releases
Angiotech
Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly
Resorbing Suture Product Line
Angiotech
announces intent to file 510(k) for its innovative 5-FU Central Venous
Catheter (CVC) based on positive results from pivotal trial
Angiotech
announces further European expansion of the Quill(TM) SRS PDO product line
Angiotech
reaches agreement with Johnson & Johnson to settle outstanding patent
litigation
Angiotech
receives favourable patent decision from New Zealand's Intellectual Property
Office
Hemo-Stream(TM)
Chronic Dialysis Catheter Receives FDA Clearance
Angiotech
announces additional diameters of sutures to further expand its Quill(TM)
SRS PDO product line
Angiotech
reports second quarter results
For the latest Quote
and News on ANPI Click
Here.
Three
Month Chart

Contacts
Angiotech Pharmaceuticals
1618 Station Street
Vancouver, BC V6A 1B6
Canada
Phone: 604-221-7676
Fax: 604-221-2330
SEC Filings
ANPI filings with the SEC can be found here.
All Fillings are current and the Company is fully reporting.
Disclaimer
SmallCapReview.com
feature stock reports are intended to be stock ideas, NOT recommendations.
Please do your own research before investing. It is crucial that you at
least look at current SEC filings and read the latest press releases.
For continuing coverage of ANPI, please sign up for our free newsletter.
Information contained in this report was extracted from current documents
filed with the SEC, the company web site and other publicly available
sources deemed reliable. For more information see our disclaimer section, a
link of which can be found on our web site. This document contains
forward-looking statements, particularly as related to the business plans of
the Company, within the meaning of Section 27A of the Securities Act of 1933
and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ
materially from the Company's expectations and estimates. The information
provided in this report is not intended for distribution to, or use by, any
person or entity in any jurisdiction or country where such distribution or
use would be contrary to law or regulation or which would subject us to any
registration requirement within such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a
Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out
to be. All materials presented on our web site and individual reports
released to the public through this web site, e-mail or any other means of
transmission are not to be regarded as investment advice and are only
for informative purposes. Before making a purchase or sale of any securities featured
on our web site or mentioned in our reports, we strongly encourage and
recommend consultation with a registered securities representative.
This is not to be construed as a solicitation or recommendation to buy or
sell securities. As with any stock, companies we select to profile involve a
degree of investment risk and volatility. Particularly Small-Caps and OTC-BB
stocks. All investors are cautioned that they may lose all or a portion of
their investment if they decide to make a purchase in any of our profiled
companies. Past performance of our profiled stocks is not indicative of
future results. The accuracy or completeness of the information on our web
site or within our reports is only as reliable as the sources they were
obtained from. The profile and opinions expressed herein are expressed
as of the date the profile is posted on site and are subject to change
without notice. No investor should assume that reliance on the views,
opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold
positions in securities mentioned herein, and may make purchases or sales in
such securities featured on our web site or within our reports. In order to
be in full compliance with the Securities Act of 1933, Section 17(b),
SmallCapReview.com will disclose in it's disclaimer, what, if any
compensation was received for our efforts in researching, presenting
and disseminating this information to our subscriber database and featuring
the report on the SmallCapReview.com web site. SmallCapReview.com
has not been compensated for its efforts in presenting the Angiotech
Pharmaceuticals profile on its website and distributing it to its
database of subscribers. SmallCapReview.com
may decide to purchase or sell shares on a voluntary basis in the open
market before, during or after the profiling period of this report.
Information presented on our web site and within our reports contain
"forward looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as “expects’”, “will,” “anticipates,”
“estimates, “believes,” or that by statements indicating certain
actions “may,” “could,” or “might” occur.
THE
READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE
INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP
SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC)
at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its
web site.
|